US Compounding Inc., Conway, AR

Is US Compounding Inc. registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility, with FDA’s note “Out of business”.

Does US Compounding Inc. hold a Arkansas pharmacy license?

State board of pharmacy records for Arkansas are not checked: the board’s license verification site answered automated requests with a firewall block, and this index does not work around blocks; no license file was found on the board’s website when checked on November 10, 2026. The Colorado State Board of Pharmacy also lists nonresident license OSP 5611 for US Compounding, Inc, Conway, AR, status Expired, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054015531 for US COMPOUNDING INC, CONWAY, AR, status CHANGE OF OWNERSHIP, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002099 for US COMPOUNDING, CONWAY, AR, status INACTIVE, as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0000899 for US Compounding, CONWAY, AR, status Closed, license A9-0001860 for US Compounding, CONWAY, AR, status Closed and license AA-0000049 for US Compounding, CONWAY, AR, status Closed, as of Nov 10, 2026.

Has US Compounding Inc. had a state board action or FDA letter?

FDA letters: no matching record found on FDA’s compounding inspections and actions page (current as of Oct 22, 2026, covering 2019 on) on Nov 15, 2026; the page lists 1 Form 483 (Feb 7, 2019) for US Compounding Inc. State board of pharmacy records for Arkansas are not checked: the board’s license verification site answered automated requests with a firewall block, and this index does not work around blocks; no license file was found on the board’s website when checked on November 10, 2026. The Colorado State Board of Pharmacy’s license dataset also lists 4 actions: “CLS Letter of Admonition” dated Mar 4, 2022, case 2021-6792 on nonresident license OSP 5611, “CLS Letter of Admonition” dated Jun 28, 2021, case 2021-2722 on nonresident license OSP 5611 and “CLS Stipulation” dated Mar 12, 2014, case 2014-254 on nonresident license OSP 5611, and more listed below.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
US Compounding Inc.
Location
Conway, AR
Type as FDA labels it
503A
FDA’s note
Out of business
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Feb 7, 2019
FDA Data Dashboard inspections
4 inspections: 3 OAI, 1 VAI; 4 published Form 483s
Form 483 text on this page
3 Form 483s, 29 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as US Compounding Inc., a 503A facility, with 1 dated action.

Document
Feb 7, 2019Form 483483 Issued 02/07/2019FDA copy (archived)

A Form 483 lists investigator observations, not a final FDA determination.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists US Compounding Inc, Conway, AR (FEI number 3006031801), matched to this page by exact name, city and state. It lists 4 inspections: 3 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Feb 7, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30060318011078477
Jul 15, 2016Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3006031801978239
Aug 21, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3006031801940793
Mar 27, 2014Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3006031801874818

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 29 numbered observations in all, across 3 inspections ending Mar 27, 2014 to Feb 7, 2019. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jan 23, 2019 to Feb 7, 2019: 10 observations

Firm on the cover
US Compounding Inc, 1270 Dons Ln, Conway, AR 72032-4753
FEI number
3006031801
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from Data Dashboard, actions page
FDA document
Read the full 483 (PDF on fda.gov); FDA also posts it as https://web.archive.org/web/20250506103522/https://www.fda.gov/media/124482/download

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

****This is a repeat observation from 08/21/2015 & 07/15/2016****

Specifically, your firm has written procedures which describe personnel and environmental monitoring. The following deficiencies in the procedure and practices were observed:

A. Your firm failed to conduct investigations related to all mold recoveries in 2018. According to your firm's 2018 Environmental Monitoring Trend Draft Report, 21 Colony Forming Unit (CFUs) counts for mold were identified in your firm's Sterile Suite (ISO 8, ISO 7 and ISO 5). Your firm's QA department documents 18 Environmental control Alert/Action Notification Reports for Environmental Monitoring excursions related to mold. However, your firm only investigated 50% of these excursions. Your firm's Director of QA/QC did not provide scientific justification as to why an investigation was not performed on all notifications. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A.Y our firm failed to clean as recommended by your firm's 503B Operations Manager after your firm received an out-of-specification for EM excursions in your fi rm's Sterile Prep Room (IS O 8) for 14 CFU (i.e . 1 1 CFU for bateria and 3 CFU for mold contamination). Your firm prepare s materials such as excipients and APIs in the Sterile Prepr Room (ISO 8). B. Your firm failed to establish cleaning procedures to prevent cross-contamination of testosterone to other drug products. C. Your fnm has not established a cleaning validation to assure your cleaning process removes chemical and microbial residues on the equipment used in your aseptic operations.

Observation 3

Aseptic processing areas are deficient in that ceilings are not smooth and/or hard surfaces that are easily cleanable.

Specifically, your firm failed to ensure the material used to caulk and seal the ceiling tiles, located in your firm's Sterile Suite, is cleanroom grade or suitable for cleanrooms that are used for aseptic filling operations. On 11/05/2018, your firm replaced 1 ceiling tile and resealed <Redacted B4> ceiling tiles in your firm's Sterile Suite (ISO 8 and ISO 7 areas), where sterile drug products are produced. The caulking is not

smooth.

Observation 4

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically ,

A.Y our firm's Media fills do not simulate the most challenging and/or stressful conditions. F or e xample, but not limited to, according to your firm's Director of Pharmacy, aseptic operations m ary occur simultaneously <R ed acted B4>. How eve r your m edia g i

I

performed under <Redacted B4> of the LAFH (IS O 5) <R eda cted B4>.

l ls ar e

B. Your firm did not conduct any dynamic smoke studies from 10/19/2015 through 11/07/2018. The airflow studies performed in November 2018 were deficient in determining if the air movement from the HEPA filters within the ISO 5 classified area, where sterile drug products are manipulated, was unidirectional. 1. In addition your firm's aseptic processing assistant, who primarily moves into ISO 5 from the ISO 7 area multiple times during routine aseptic processing (approx. <Redacted B4>), did not move (static conditions) during dynamic smoke studies. 2. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include validation of the aseptic and sterilization process.

Specifically,

A. A. Your firm does not have any process validations for the aseptic production of your fir m's suspension products. Including, but are not limited to:1. Methylprednisolone 80mg/mL PF Sterile Injectable, 2. Methylprednisolone/Lidocaine 40mg/1%/mL Sterile Injectable, 3. Methylprednisolone/Lidocaine 80mg/1%/mL Sterile Injectable, 4. Betamethasone 7mg/mL Combo Sterile Injectable, 5. Triamcinolone Acetonide PF 50mg/mL Sterile Injectable, 6. Triamcinolone Diacetate 40mg/mL PF Sterile Injectable, 7. Triamcinolone Diacetate 40mg/mL Sterile Injectable, 8. Triamcinolone Diacetate 80 mg/mL Sterile Injectable, 9. <Redacted B4>/Lidocaine 150mg/mL 150mg/1%/mL Sterile Injectable, 10. Dexamethasone Acetate 8mg/mL Sterile Injectable, 11. Dexamethasone Acetate 16mg/mL Sterile Injectable, 12. Dexamethasone Acetate Sodium Phosphate Combo 8mg/4mg/mL Sterile Injectable

Methylprednisolone 80mg/mL PF Sterile Injectable

Triamcinolone Diacetate 80 mg/mL Sterile Injectable

_J,

B. ...

Read the full 483 (PDF on fda.gov)

Observation 6

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

***This is a repeat observation from 07/15/2016****

Specifically, your firm failed to investigate and appropriately determine if batches can be released for Sterility and Potency final release out-of-specifications. For example, but are not limited to:

4 IDl( f syringes of this lot was distributed to the end user for pediatric patients use.

After the initiation of this investigation, your fnm found particulate matter in your retain sample for previous lots for morphine oral solution. Your fnm used an outside microscopy contract laboratory who conducted the analysis ofuyringes containing m01phine oral solution. On 12/06/2018, your fnm received a confnmatory report from the outside microscopy contract laboratory who conducted the analysis of 4 b) ( ) containing m01phine oral solution:

s

6) _l 4) I for Lot #20181804@9 and Lot #20182009@6 "supported brown particles consistent with biological material, possibly fungus or mold". ...

Read the full 483 (PDF on fda.gov)

Observation 7

The written stability program for drug products does not include reliable, meaningful and specific test methods.

Specifically, your firm failed to test preservative content at expiry to verify the preservative system is effective and protects the product over its shelf life under expected conditions of use.

Observation 8

Repo1ts of analysis from component suppliers are accepted in lieu of testing each component for confo1mity with all appropriate written specifications, without perfo1ming at least one specific identity test on each component and establishing the reliability of the supplier's analyses through appropriate validation of the supplier's test results at appropriate intervals.

Specifically, your fnm relies on your vendor supplier's Ce1tificate of Analysis (COAs) for the use of drug components, without conducting any addition testing (e.g. identity, potency, sterility, and endotoxin) prior to use in your fnm's aseptic operations. In addition, your fnm does not have a quality agreement with each supplier.

Observation 9

The quality control unit lacks the responsibility and authority to approve and reject all components, chug product containers, closures and chug products.

S pecifi call y,

****THIS IS A REPEAT OBSERVATION FROM 07/15/2016****

Your fnm relies on the supplier's COA is used in lieu of conducting any specific tests on chug components to establish the identity, purity, strength, and quality of these components which are used in the production of non-sterile chug products. In addition, your fnm does not have a Quality Agreement with these vendors. Fmthe1more, testing and release of chug product for distribution do not include appropriate laboratory dete1mination of satisfacto1y confo1mance to the final specifications, identity and sb'ength of each active ingredient prior to release.

Observation 10

The labels of your outsourcing facility's chug products are deficient.

The labels of some of your outsourcing facility's ch11g products do not include info1mation required by section 503B(a)(l 0)(A). Specifically,

A. The proportion or quantity of each inactive ingredient is not included on some labels. Example o f product labels that do not contain this information include: 1. GI Cocktail-Belladonna Alkaloids: Antacid:Lidocaine 35 mL Oral Bottle, 2. Acetaminophen Oral 240 mg/7.5 mL Oral Syringe, 3. Magic Mouthwash-Lidocaine+Diphenhydramine+Antacid 5 mL Oral Syringe, 4. Promethazine Topical Gel 25ml/ml 1 mL Topical Syringe, 5. Simethicone 120 mg/1.8 mL Oral Syringe, 6. Multivitamin+Iron 1 mL Oral Syringe

B. The dosage form of the drug is not included on some labels. Examples of products labels that do

not contain this information include: 1. Neostigmine 5 mg/5 mL Single Use Syringe, 2. Glycopyyrolate 1 mg/5 mL Single Use Syringe, 3. Succinylcholine 200 mg/10 mL Single Use Syringe, 4. GI Cocktail -Antacid:Lidocaine 3: 1 40 mL Syringe, 5. LET Gel 4%/0.1%/0.5% 3 mL Single Use Syringe

Neostigmine 5 mg/5 mL Single Use Syringe ...

Read the full 483 (PDF on fda.gov)

Inspection Aug 10, 2015 to Aug 21, 2015: 11 observations

Firm on the cover
US Compounding Inc. Street Address: 1270 Don's Lane. City, State, Zip Code, Country: Conway AR 72032 Type Establi shment Inspected: Outsourcing Facility I Titis d obser
FEI number
3006031801
FDA district office on the cover
Expressway, Suite 300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equ ipment to produce aseptic conditions.

Specifically,

A.Y our firm's failed to use sporicidal disinfectants in response to any environmental monitoring findings of spore-forming organisms. When the past 6 months of cleaning logs were reviewed, no documentation of use of a sporicidal agent could be demonstrated prior to March of2015.5 of 11 initial sterility failures from 2014 to present have occurred due to the presence of spore forming organisms. A comprehensive investigation was not performed. These initial sterility failures are summarized below:Testosterone 37.5mg Pellet produced on 11106/2014 (Lot Number: 20140611@8) tested positive for Bacillus infantis I. Methylpred I Lido 40mg/l%/ml produced on:.00/13/2014 (Lot Number: 20141305@3) tested positive for Bacillus thuringiensis.Guaifenesin 5% produced on 04/25/2014 (Lot Number: 04252014@14) tested positive for Bacillus simplex. Ketoprofen 10% produced on 03/24/2014 Lot Number: 03242014@3) tested positive for Bacillus circulans. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

A. Between 10/1/14 and 8/10/15, contact and viable air monitoring exceeded action limits without documentation of a complete investigation, implementation and reassessment in response to excursions above action limits for environmental monitoring of contact surfaces and viable air in the aseptic processing areas. Monitoring included 33 instances actionable contamination ranging up to 49 CFU contact plate inside the ISO 5 redacted (b)(4), 271 CFU contact plate in the redacted (b)(4) housed in the IS0 8 Glass Storage and Prep and 63 CFU for viable air.

B. Between 10/1/14 and 8/10/15, personnel monitoring exceeded action limits during the aseptic processing of sterile products to include 22 instances ranging up to 64 CFU for Gloves and 52 CFU for Personnel Clothing and Garb. You failed to investigate and take appropriate actions after counts for microbial contamination exceeded action limits.

b 4 where aseptic processing of sterile products is performed.

Observation 3

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically,

A. You failed to consistently review and investigate alerts when the pressure differentials dropped below the minimum set points of redacted (b)(4) W.C. You reported the alarms for the minimum air pressure differential set points were eliminated during a correction made in June 2015, rendering the alarms non-functional. The current Controlled Environment Performance Test and Certification Report performed on 8/3-4/2015 found that three of the b)(4) air pressure differential gauges were not functioning properly or were in need of calibration including the gauges between the ISO 7 Cleanrooms Redacted (b)(4) and ISO 7 Anteroom 114 and the ISO 8 Chemical Storage and the Unclassified Hall.

r

You failed to consistently review and investigate alerts when the pressure differentials dropped below the minimum set points of redacted (b)(4) W.C. You reported the alarms for the minimum air pressure differential set points were eliminated during a correction made in June 2015, rendering the alarms non-functional. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile a re not established .

Specifically,

A.Your firm does not perform media fills that simulate production or most challenging conditions. During production, a Redacted (b)(4) is Redacted (b)(4) During this process, the vials to be lyophilized, Redacted (b)(4) . No media fills simulating this process is being conducted. Additionally, your media fills are not conducted to simulate the door opening and closing Redacted (b)(4) times in a single minute as observed between 2:30 and 2:55 PM on 08/11/2015. Instead, your media fills are conducted Redacted (b)(4) . Furthermore, your firm did not begin to implement the use of media fills until 09/24/2014. Additionally, your firm does not qualify operators' via media fills prior to conducting aseptic processes. As of 09/08/2014 the firm hired a new operator Redacted (b)(4) This operator was qualified for aseptic filling on 03/24/2015 and filled FENTANYL PF 50 Ml (Lot Number: 20152403@28) on that same day. However, until 04/13/2015 Redacted (b)(4) was not qualified by a media fill. ...

Read the full 483 (PDF on fda.gov)

Observation 5

. Written procedures for sampling and testing plans are not followed for each drug product.

Specifically, you failed to conduct a 100% visual inspection of Papaverine 3.6mg/mL +Phentolamine 0.4mg/mL + Atropine 0.04mg/mL lot 20152403@12 prior to its initial distribution of vials on 4/16/15 as office stock. SOP Sl9 entitled Finished Product Testing Requirements, states in Section 9.1, "Immediately after compounding, and as a condition of release, each CSP unit, where possible should be inspected REDACTED (b)(4) for evidence of visible particulates or other foreign matter." During the inspection, you retrospectively inspected the remaining inventory of lot 20152403@12 and found REDACTED (b)(4) units passed and 18 units failed visual inspection.

Furthermore, during the visual inspection of the subsequent lot of Papaverine 3.6mglmL +Phentolamine 0.4mg/mL + Atropine 0.04mglmL lot (b 4 (b)(4) v1as found on 8/18/15 to have failed visual inspection with a failure rate of 57.5% with 114 units passing and 73 units failing visual inspection due to visible fiber like particles.

Observation 6

Control procedures are not established which validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in~process material and the drug product.

Specifically, review of2015 complaints revealed that 55 of 108 of the firm's complaints relate to broken testosterone, estradiol, and progesterone pellets. When dbcussed with you firm they stated that a e number of formulation changes have been made to the testosterone pellets in order to address the complaints. However, your firm released batches of pellets without assessing the manner these formulation alterations affected product efficacy. In addition, no dissolution studies were conducted. An example of these alterations for Testosterone 200 MG Pellets is listed below:

1) Lot 20132210@12 is formulated with Povidone, Stearic Acid and Testosterone. 2) Lot 20141002@37 is formulated with Stearic Acid and Testosterone. 3) Lot 20141508@35 is formulated with Stearic Acid, Testosterone and Magnesium

Stearate

4) Lot 20152601@1 0 is f ormulated with Stearrinc Acid , testosterone and Magnesium Stearate. ...

Read the full 483 (PDF on fda.gov)

Observation 7

There is no written testing program designed to assess the stability characteristics of drug products.

Specifically, we observed the preparation of Morphine 2mg/2ml (lmglml) PF (preservative free) (Lot Number: 20151008@2) on 08/10/2015. This procluct is assigned a 180 day BUD without supporting stability data. Additionally, according to your firm's production logs, other examples of products assigned a BUD of 180 day without supporting stability data include Betamethasone PF 6MGIML (Lot Number: 20152602@19) and Cupric sulfate pentahydrate PF (Lot Number: 20150402@5) 1.57 M.

Your firm's VP of Operations indicated that approximately H4 sterile products are produced by your firm. The firm indicated that of all the products produced, only two (methylprednisolone acetate 80 mg/ml + Lidocaine 1% and Medroxyprogesterone acetate 150 mg/ml + Lidocaine 1%) are supported by stability indicating studies. Additionally, of the approximately REDACTED (b)(4) sterile products, only 17 have end-point sterility (performed for REDACTED (b)(4) ).

Observation 8

Equipment used in the manufacture, processing~ packing or holding of drug products is not of adequate size and suitably located to facilitate operations for its

Specifically,

Your firm employs a REDACTED (b)(4) water system for a REDACTED (b)(4) used for cleaning of instruments, beakers, and final containers/closures used in aseptic processes. Your REDACTED (b)(4) water system is inadequate due to the following:

A. Your firm lacks qualification or validation for the water system, despite your firm utilizing the system in the production process since August 2012.

C. There are no filters on pressure relief valve for the holding tanks to prevent intake of Contaminants. There are no filters on pressure relief valve for the holding tanks to prevent intake of Contaminants.

Observation 9

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

Specifically, on 08/14/2015, your VP of Operations indicated that they produce approximately REDACTED (b)(4) sterile drug products containing presertative; however no preservative indicating stu dies ha ve been performed. Your firm failed to test tho preservative content in batches at time of release.

Observation 10

The labels of your outsourcing facility's drug products are deficient. The labels of your outsourcing facility's drug products are deficient.

Specifically, the following infonnation is not found on some of your drug product labels:

The statements "This is a compounded drug" and ''Not for resale."

The containers of some of your drug products do not contain information to facilitate adverse event reporting: www.fda.gov(medwatch and l-800-FDA-1088.

a

Examples of drug product labels and containers that do not contain the above information: Examples of drug product labels and containers that do not contain the above information:

911'1.0YtE(S)aiOHo\ll.llE " • -~· . ?<."J.

nt. Tl! ISSUED

A. Pain Cream #600- Tablet-Based Formula, Meloxicam 0.09%, Topiramate 2.5%, Gabapentin 6% in Lidocaine/Prilocaine 2.5%/2.5%

B. Testosterone 20% Gel, 30 OM C. Diethylstilbestrol 0.5 mg Capsule D.Enrofloxacin/Ketoconazole/Triamcinolone Otic in Lanolin 0.5/0.1% Ointment

Observation 11

ix I

Your outsourcing facility has not submitted a report to FDA identifying product produced during the previous s months as required by section 503B(bX2XA).

I od I

Specifically, the following products were produced and not identified on your report for the reporting peri 12/1/14-5/31115, which was submitted on June 19,2015:

A. Pain Cream #600- Tablet-Based Fonnula, Meloxicam 0.09%, Topiramate 2.5%, Gabapentin 6% Lidocaine/Prilocaine 2.5o/o/2.5% : Lot Number 20151008@10, Expiry Feb. 6th, 2016, Shipped 08/20/2015 B. Testosterone 200/o Gel, 30 GM : Lot Number 20151607@31, Expiry Jan. 200, 2016, Shipped 08/20/2015 C.Diethylstilbestrol 0.5 mg Capsule : Lot Number 08052015@66, Expiry Feb. 1st. 2016, Shipped 08/19/2015

in ed

ed

ed

Inspection Mar 17, 2014 to Mar 27, 2014: 8 observations

Firm on the cover
US Compoundinq Inc Street 1270 Don's Lane, Conwa y, AR 72 032
FEI number
3006031801
Establishment type on the cover
Outsourcing facility
FDA district office on the cover
4040 North Central Expressway, Suite 300 Dallas, TX 75204
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Protective apparel is not worn as necessary to protect drug products from contamination.

Specifically, On 3/19/14 during tile set-up of Omnipaque (iohexol) 240mg/ml injectable in Clean Room <Redacted B4> technician was observed with exposed skin in the ISO 5 laminar flow hood setting up equipment and supplies. Approximately 1/4 inch of skin was exposed across the length of the technician's forehead above the goggles.

Observation 2

Procedures designed to prevent microbiological coniamination of drug products purporting to be sterile are not established.

Specifically, It was observed on 3/17/14, a technician unnecessarily handling sterile rubber stoppers. A technician was observed band · stoppering vials <Redacted B4>) of HCG/B12 lot 20141703@3; 10ml CONCENTRATE 10,000 UNITS/1200mcg/ml injectable in the ISO 5 laminar flow hood.

Observation 3

Buildings used in the mannfucture, processing, packing or holding of drug products are not maintained in a clean and sanitary condition.

Specifically, It was observed on 3/17 & 18/2014 <Redacted B4> ISO 5 laminar flow hoods contained white residue streaks and blotches on the metal grid of the HEPA filters. An amber colored residue was observed stuck in the metal grids in ISO laminar flow hood #2 approximately 4 inches in length along the bottom right. Sterile products were being produced in die 180 5 laminar flow hoods on 3/17/2014.

Observation 4

Container closure systems do not provide adequate protection against foreseeable external factors in storage and use that can cause deterioration or contamination of the drug product.

Specifically,

It was observed on 3/17/14, finished product viaIs ofBetamethasone Sodium Phosphate/ Acetate lot 20141302@2 <Redacted B4> vials), in a tote on the floor label <Redacted B4> ; drying in bins layered in blue wipes. The firm explained that the vials were previously soaked in a tote o to remove any residues before labeling. There are no operating procedures for this operation. Your firm cannot be assured that the finished drug products in the prior to labeling will not be contaminated by the.

Observation 5

Each batch of drug product purporting to be sterile and pyrogen-free is not laboratory tested to determine conformance to such requirements.

Specifically,

a) Between 12120/2013-03/19/2014, your firm has release <Redacted B4> of sterile finished products using an endotoxin test method that has not been validated and is performed by a contract laboratory. Your firm does not supply your contract testing laboratory with information regarding product specific drug dosing and route of administration that would be used to calculate the maximum valid dilution. Without this calculation the testing laboratory is unable to perform a valid assay for endotoxin.

b) Between 12/20/2013-03/19/2014, your firm release <Redacted B4> of sterile finished products using USP <71> for sterility testing performed by a contract laboratory. Your firm used bacteriostatic and fungistatic assay suitability testing documented for either other firm's products using the same formulation or using different formulations as the assay suitability confirmation for your products. Since 12/20/2013, the following lots have been released using the sterility testing suitability generated from different products:

Observation 6

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications prior to release.

Specifically,

A 100% visual or automated inspection of sterile finished products is not documented by your firm. Furthennore, your firm has not established a visual inspection procedure and there is no documentation of visual inspection training qualification of the technicians performing the visual inspection of sterile finished products.

Observation 7

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the equipment to produce aseptic

conditions.

Specifically,

a) <Redacted B4> is the only disinfectant used to clean and disinfect in the ISO 5 Class 100 Laminar flow hood. There is no sporicidal disinfectant used in the ISO 5 Class 100 laminar flow hoods used for sterile drug preparations.

b) On 3/18/14, a pharmacy technician was observed performing an inadequate disinfection of the ISO 5 Laminar flow hood used for aseptic processing of sterile drug products. The pharmacy technician was observed only wiping the table top work surface, ceiling and sides with a sterile wipe containing , disinfectant. There was no disinfection ofthe back surface of the laminar flow hood where stains were observed one metal grid. Standard operating procedure S4, titled Cleaning and Sanitization of Cleanrooms and Sterile Prep" version 7 section 7.6.1.3.6 effective 2/6/14 requires cleaning of the back metal grid.

Observation 8

The labels for the drug products and drug product containers you produce do not contain information required by section 503B(a)(10)

Specifically,

I. The statements, "This is a compounded drug," "Not for resale," and Office use only" are not on your drug product labels. Labels for the following drug products either do not contain these statements or contain variations such as "This medication was compounded in our pharmacy for use by a licensed practitioner only," or "This compounded preparation may not be resold:"

0 Methylprednisolone/Lidocaine, 40 mg/1%/ruL, 10 mL Multi-dose Vial D Atropine Inj PF "COMPOUND" 1ml vial 0.4mg/mL

O Lincomycin/Lidocaine Hydrochloride, 300mg/1%/mL, 10mL Sterile Multi-dose Vial

D Dexamethasone 4mg/mL, Dexamethasone Sodium Phosphate 120mg/30mL D Trace Elements-4, 10mL Multi-dose Vial

2. Your drug product container label(s) do not contain information to facilitate adverse event reporting: www.fda.gov/medwatch and 1-800-FDA-1088 For example:

O Atropine sulfate 0.4 mg/mL Preservative Free, Single use 1 mL Vial

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Arkansas are not checked: the board’s license verification site answered automated requests with a firewall block, and this index does not work around blocks; no license file was found on the board’s website when checked on November 10, 2026.

Nonresident licenses in other states

These boards list a nonresident license whose record names this pharmacy’s own name, city and state.

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 5611OSPUS Compounding, IncConway, ARExpired

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054015531LICENSED PHARMACYUS COMPOUNDING INCCONWAY, ARCHANGE OF OWNERSHIP

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002099NONRESIDENT PHARMACYUS COMPOUNDINGCONWAY, ARINACTIVE

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0000899Non Resident PharmacyUS CompoundingCONWAY, ARClosed
A9-0001860Non Resident PharmacyUS CompoundingCONWAY, ARClosed
AA-0000049Outsourcing Facility-PharmacyUS CompoundingCONWAY, ARClosed

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.